Masimo Co. (NASDAQ:MASI) Stock Holdings Decreased by WINTON GROUP Ltd

WINTON GROUP Ltd decreased its stake in shares of Masimo Co. (NASDAQ:MASI) by 42.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,410 shares of the medical equipment provider’s stock after selling 3,302 shares during the period. WINTON GROUP Ltd’s holdings in Masimo were worth $729,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Smartleaf Asset Management LLC lifted its holdings in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 60 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 64 shares during the last quarter. Blue Trust Inc. boosted its holdings in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Masimo by 0.8% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock valued at $1,622,000 after purchasing an additional 82 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its holdings in shares of Masimo by 0.8% during the fourth quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock worth $1,728,000 after purchasing an additional 83 shares during the period. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Piper Sandler increased their price target on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Raymond James raised their price target on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Stock Down 2.9 %

Shares of Masimo stock opened at $163.55 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $194.88. The business’s fifty day moving average price is $174.79 and its two-hundred day moving average price is $161.39. The company has a market capitalization of $8.82 billion, a P/E ratio of 112.79 and a beta of 1.04.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to analysts’ expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. As a group, research analysts forecast that Masimo Co. will post 4.1 EPS for the current year.

Insider Activity at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.70% of the company’s stock.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.